At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
09606 DUALITYBIO-B
Closed Easter Monday 04-02 16:08:21
323.600
+2.400
+0.75%
High331.000Low313.800Vol1.03M
Open321.200D1 Closing321.200Amplitude5.35%
Mkt Cap29.17BTradable Cap29.17BTotal Shares90.14M
T/O333.11MT/O Rate1.14%Tradable Shares90.14M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
HK Pharma Stocks Gained. CSPC Pharma Up 13%; Lepu Bio Up 7%; Hengrui Pharma And Junshi Bio Up 6%; HBM, Beigene, Sihuan Pharm Up 5%
Tiger Newspress  ·  03-27
HK Pharma Stocks Gained. CSPC Pharma Up 13%; Lepu Bio Up 7%; Hengrui Pharma And Junshi Bio Up 6%; HBM, Beigene, Sihuan Pharm Up 5%
DualityBio-B Maintains Outperform Rating with HK$430 Target from CICC
Stock News  ·  03-27
DualityBio-B Maintains Outperform Rating with HK$430 Target from CICC
Stock Track | Duality Biotherapeutics Soars 5% Intraday as Analysts Boost Estimates After Earnings Report
Stock Track  ·  03-27
Stock Track | Duality Biotherapeutics Soars 5% Intraday as Analysts Boost Estimates After Earnings Report
Earnings Update: Duality Biotherapeutics, Inc. (HKG:9606) Just Reported And Analysts Are Boosting Their Estimates
Simply Wall St.  ·  03-27
Earnings Update: Duality Biotherapeutics, Inc. (HKG:9606) Just Reported And Analysts Are Boosting Their Estimates
HK Pharma Stocks Gained. XuanzhuBio Up 9%; Xtalpi, Lepu Bio And Ascletis Up 6%; Akeso Up 5%; Skb Bio Up 4%.
Tiger Newspress  ·  03-26
HK Pharma Stocks Gained. XuanzhuBio Up 9%; Xtalpi, Lepu Bio And Ascletis Up 6%; Akeso Up 5%; Skb Bio Up 4%.
Dualitybio (9606.HK) Announces 2025 Annual Results
THOMSON REUTERS  ·  03-24
Dualitybio (9606.HK) Announces 2025 Annual Results
Press Release: DualityBio (9606.HK) Announces 2025 Annual Results
Dow Jones  ·  03-24
Press Release: DualityBio (9606.HK) Announces 2025 Annual Results
Stock Track | Duality Biotherapeutics Plummets 5.04% Intraday on Widened 2025 Loss and Revenue Decline
Stock Track  ·  03-24
Stock Track | Duality Biotherapeutics Plummets 5.04% Intraday on Widened 2025 Loss and Revenue Decline
HK Pharma Stocks Gained. Wuxi XDC Up 8%; Wuxi AppTec Up 7%; Transthera And HBM Up 5%; Keymed Bio And Innocare Up 4%; Wuxi Bio And Remegen Up 3%
Tiger Newspress  ·  03-24
HK Pharma Stocks Gained. Wuxi XDC Up 8%; Wuxi AppTec Up 7%; Transthera And HBM Up 5%; Keymed Bio And Innocare Up 4%; Wuxi Bio And Remegen Up 3%
BRIEF-Duality Biotherapeutics FY Revenue Rmb1.85 Billion
Reuters  ·  03-23
BRIEF-Duality Biotherapeutics FY Revenue Rmb1.85 Billion
BRIEF-Duality Biotherapeutics Inc Says Si Wen Tendered Resignation As Exec Director
Reuters  ·  03-23
BRIEF-Duality Biotherapeutics Inc Says Si Wen Tendered Resignation As Exec Director
DUALITYBIO-B Reports 2025 Revenue of Approximately 18.52 Billion Yuan, Marking Significant Pipeline and Operational Progress
Stock News  ·  03-23
DUALITYBIO-B Reports 2025 Revenue of Approximately 18.52 Billion Yuan, Marking Significant Pipeline and Operational Progress
DualityBio Posts Wider 2025 Loss on Fair-Value Impact; Core ADC Programs Advance Toward Commercial Stage
Bulletin Express  ·  03-23
DualityBio Posts Wider 2025 Loss on Fair-Value Impact; Core ADC Programs Advance Toward Commercial Stage
DUALITYBIO-B (09606) Announces Dr. Hua Haiqing Appointed as Executive Director
Stock News  ·  03-23
DUALITYBIO-B (09606) Announces Dr. Hua Haiqing Appointed as Executive Director
Duality Biotherapeutics FY2025 loss attributable to owners widened 146.99% to RMB 2,594,827,000
Reuters  ·  03-23
Duality Biotherapeutics FY2025 loss attributable to owners widened 146.99% to RMB 2,594,827,000
Duality Biotherapeutics reports DB-1303 Phase 3 trial meets primary PFS endpoint
Reuters  ·  03-23
Duality Biotherapeutics reports DB-1303 Phase 3 trial meets primary PFS endpoint
Duality Biotherapeutics - Loss for Year Attributable RMB2.59 Bln
THOMSON REUTERS  ·  03-23
Duality Biotherapeutics - Loss for Year Attributable RMB2.59 Bln
Duality Biotherapeutics Inc - Si Wen Tendered Resignation as Executive Director
THOMSON REUTERS  ·  03-23
Duality Biotherapeutics Inc - Si Wen Tendered Resignation as Executive Director
Duality Biotherapeutics appoints HUA Haiqing as executive director and names ZHANG Shaoren CFO
Reuters  ·  03-23
Duality Biotherapeutics appoints HUA Haiqing as executive director and names ZHANG Shaoren CFO
Duality Biotherapeutics Inc - Zhang Shaoren Has Been Appointed as CFO
THOMSON REUTERS  ·  03-23
Duality Biotherapeutics Inc - Zhang Shaoren Has Been Appointed as CFO

Introduction

Company Name.
DUALITYBIO-B
Affiliated Markets:
SEHK
Listing Date:
--
Main Business:
Duality Biotherapeutics Inc is an investment holding company principally engaged in clinical-stage biopharmaceuticals. The Company is dedicated to the development of antibody-drug conjugate (ADC) innovative therapeutics to treat cancer and autoimmune diseases. The Company's primary drug product candidates include DB-1303/BNT323, DB-1311/BNT324, DB-1310, DB-1305/BNT325, DB-1419 and DB-2304. The Company's products are mainly used for the targeted treatment of endometrial cancer (EC), breast cancer (BC), small-cell lung cancer (SCLC), castration-resistant prostate cancer (CRPC), esophageal squamous cell carcinoma (ESCC), as well as head and neck squamous cell carcinoma (HNSCC). The Company principally conducts its businesses in domestic and overseas markets.
Issue price:
--